This study represents the largest PD AAO meta-analysis in European-ancestry populations to date. 5 key findings →
Design: meta-analysis Participants: 50,859 Evidence: high
Full summary, score breakdown and related studies → Original source
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Genome-wide association studies (GWAS) have identified many loci that contribute to the risk of neurodegenerative diseases. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Forty-eight studies, mostly of weak- or moderate-quality, met inclusion criteria. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
From 464 identified records, 30 peer-reviewed primary studies met all eligibility criteria following the exclusion of low-quality sources and unindexed preprints. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Simulation-based validation demonstrates the framework’s analytical capability. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
SGLT2 inhibitors and GLP-1 receptor agonists have the greatest effect on cognition in T2DM, and the multi-component exercise as the most effective lifestyle component. 3 key findings →
Design: meta-analysis Participants: 213,604 Evidence: high
Full summary, score breakdown and related studies → Original source
Eligible studies reported MACE or dementia outcomes in adults ≥ 50 years for at least one of three intervention classes (RZV, SGLT2i, GLP-1 RA) versus placebo or active comparator, with follow-up ≥ 6 months. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Multidomain interventions have small but consistent beneficial effects on cognitive measures, suggesting the potential to reduce cognitive impairment and dementia risk. 3 key findings →
Design: systematic review Participants: 23,209 Evidence: high
Full summary, score breakdown and related studies → Original source
Insomnia disorder affects approximately 10–20% of adults and is usually chronic. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
In brain, inverse-variance random-effects meta-analysis (DerSimonian–Laird) across six independent postmortem adult-brain GEO cohorts (GSE33000, GSE132903, GSE173955, GSE159699, GSE5281, GSE48350) yielded 458 analyzable panel genes, 167 at Benjamini–Hochberg FDR < 0.05, and 141 high-confidence genes (FDR < 0.05, measured in at least three cohorts, direction-concordant in at least 70% of cohorts, and nominally significant in at least two cohorts). 1 key finding →
Design: meta-analysis Participants: 329 Evidence: high
Full summary, score breakdown and related studies → Original source
The ability to decode others’ emotions from multisensory cues is central to social functioning. 3 key findings →
Design: systematic review Participants: 1,511 Evidence: high
Full summary, score breakdown and related studies → Original source
16/100
Parkinson disease (PD) was examined in four primary adult-brain GEO cohorts (GSE49036, GSE20141, GSE8397, GSE7621) using a frozen 468-gene redox, metal, xenobiotic, and barrier panel. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Of 2,496 records screened, 26 studies met eligibility, comprising >84,000 older adults across 10 countries: United States, South Korea, United Kingdom, France, Spain, Sweden, Netherlands, Taiwan, Germany, and Japan. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Neuroinflammation is a hallmark of Alzheimer’s disease (AD); however, which neuroinflammatory effectors are consistently altered across independent human cohorts, brain regions, and microglial states—and can be engaged by available compounds—remains incompletely defined. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Affective symptoms, such as depression, anxiety and apathy, are highly prevalent in cognitively impaired Lewy body disease (LBD) groups, including Parkinson’s disease dementia and dementia with Lewy bodies. 2 key findings →
Design: systematic review Participants: 785 Evidence: high
Full summary, score breakdown and related studies → Original source
The prevalence of dementia and Parkinson’s disease in Russia varies widely depending on diagnostic method, age group, and study design. 2 key findings →
Design: meta-analysis Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source
Idiopathic normal pressure hydrocephalus (iNPH) is a potentially reversible cause of gait impairment, cognitive decline, and urinary dysfunction in older adults, yet identifying patients most likely to benefit from cerebrospinal fluid (CSF) diversion remains a major diagnostic challenge. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Face processing abilities are critical for social interaction, yet impairments are common across dementia syndromes and constitute a core diagnostic feature of some neurocognitive disorders. 5 key findings →
Design: systematic review Participants: 3,810 Evidence: high
Full summary, score breakdown and related studies → Original source
Consequently, changes in mitochondrial DNA copy number (mtDNA-CN), the number of mtDNA genomes per cell or tissue sample, are associated with diseases ranging from cancer and obesity to psoriasis and all-cause mortality. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Irrespective of ERG modality, ADRD was consistently associated with retinal dysfunction marked by impaired synaptic transmission and delayed neural processing across retinal circuits. 3 key findings →
Design: meta-analysis Participants: 18 Evidence: high
Full summary, score breakdown and related studies → Original source
News headlines from many nations, including the United States, Germany, Australia, and the United Kingdom, suggest that we are facing a loneliness epidemic (http://www.campaigntoendloneliness.org/loneliness-research, http://www.spiegel.de/international/germany/germany-faces-epidemic-of-lonely-and-isolated-seniors-a-876635.html, https://startsat60.com/health/new-survey-reveals-australias-loneliness-epidemic, http://www.huffingtonpost.com.au/tania-de-jong/loneliness-is-the-global-epidemic-of-our-times), leading to the important question of whether there is evidence to support such a claim and, if so, whether we are facing a public health crisis. 5 key findings →
Design: meta-analysis Participants: 300,000 Evidence: high
Full summary, score breakdown and related studies → Original source
For mild to moderately severe AD, the results of the study suggested that all three treatments were beneficial when assessed using cognitive outcome measures. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →